logo BDSP

Base documentaire

  1. Diagnosis and treatment of prostatitis in Canada.

    Article - En anglais


    There is a general consensus among physicians that the present management of chronic prostatitis is dismal.

    We undertook a survey of Canadian primary care physicians (PCPs) and urologists to determine the degree and source of frustration and to analyze present practice patterns in this disease.


    Five thousand PCPs and all 545 Canadian urologists were asked to complete a comprehensive computer-assisted telephone survey that explored practice characteristics, attitudes, and diagnostic and treatment strategies in the management of prostatitis.

    Randomization of attribute banks, adherence to questionnaire routing, validation by on-site monitoring, and possible bias were addressed.


    Completed interviews were obtained from 10% of PCPs and 28% of urologists.

    PCPs see on average 3.5 (median 2) patients with prostatitis per month and urologists see on average 21.8 (median 11) patients with prostatitis per month.

    All physicians experience significantly more frustration in treating prostatitis than they do in treating patients with benign prostatic hyperplasia (BPH) and prostate cancer, and they perceive that prostatitis affects patients'quality of life significantly more than BPH and almost as much as prostate cancer.

    The degree of frustration and unhappiness in dealing with prostatitis is driven by a lack of confidence and comfort in their ability to accurately diagnose and subsequently rationalize treatment. (...)

    Mots-clés Pascal : Prostatite, Chronique, Triméthoprime, Chimiothérapie, Association médicamenteuse, Sulfaméthoxazole, Canada, Amérique du Nord, Amérique, Traitement, Diagnostic, Homme, Mâle, Sulfamides, Sulfonamide, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie

    Mots-clés Pascal anglais : Prostatitis, Chronic, Trimethoprim, Chemotherapy, Drug combination, Sulfamethoxazole, Canada, North America, America, Treatment, Diagnosis, Human, Male, Sulfanilamide derivatives, Sulfonamide, Male genital diseases, Urinary system disease, Prostate disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0011529

    Code Inist : 002B14E02. Création : 31/05/1999.